Rab31-dependent regulation of transforming growth factor ß expression in breast cancer cells.
Breast cancer
EMT
GTPase
Rab31
TGF-ß signaling
Journal
Molecular medicine (Cambridge, Mass.)
ISSN: 1528-3658
Titre abrégé: Mol Med
Pays: England
ID NLM: 9501023
Informations de publication
Date de publication:
14 12 2021
14 12 2021
Historique:
received:
29
09
2021
accepted:
01
12
2021
entrez:
15
12
2021
pubmed:
16
12
2021
medline:
22
3
2022
Statut:
epublish
Résumé
The small GTP-binding protein Rab31 plays an important role in the modulation of tumor biological-relevant processes, including cell proliferation, adhesion, and invasion. As an underlying mechanism, Rab31 is presumed to act as a molecular switch between a more proliferative and an invasive phenotype. This prompted us to analyze whether Rab31 overexpression in breast cancer cells affects expression of genes involved in epithelial-to-mesenchymal transition (EMT)-like processes when compared to Rab31 low-expressing cells. Commercially available profiler PCR arrays were applied to search for differentially expressed genes in Rab31 high- and low-expressing CAMA-1 breast cancer cells. Differential expression of selected candidate genes in response to Rab31 overexpression in CAMA-1 cells was validated by independent qPCR and protein assays. Gene expression profiling of key genes involved in EMT, or its reciprocal process MET, identified 9 genes being significantly up- or down-regulated in Rab31 overexpressing CAMA-1 cells, with the strongest effects seen for TGFB1, encoding TGF-ß1 (> 25-fold down-regulation in Rab31 overexpressing cells). Subsequent validation analyses by qPCR revealed a strong down-regulation of TGFB1 mRNA levels in response to increased Rab31 expression not only in CAMA-1 cells, but also in another breast cancer cell line, MDA-MB-231. Using ELISA and Western blot analysis, a considerable reduction of both intracellular and secreted TGF-ß1 antigen levels was determined in Rab31 overexpressing cells compared to vector control cells. Furthermore, reduced TGF-ß activity was observed upon Rab31 overexpression in CAMA-1 cells using a sensitive TGF-ß bioassay. Finally, the relationship between Rab31 expression and the TGF-ß axis was analyzed by another profiler PCR array focusing on genes involved in TGF-ß signaling. We found 12 out of 84 mRNAs significantly reduced and 7 mRNAs significantly increased upon Rab31 overexpression. Our results demonstrate that Rab31 is a potent modulator of the expression of TGF-ß and other components of the TGF-ß signaling pathway in breast cancer cells.
Sections du résumé
BACKGROUND
The small GTP-binding protein Rab31 plays an important role in the modulation of tumor biological-relevant processes, including cell proliferation, adhesion, and invasion. As an underlying mechanism, Rab31 is presumed to act as a molecular switch between a more proliferative and an invasive phenotype. This prompted us to analyze whether Rab31 overexpression in breast cancer cells affects expression of genes involved in epithelial-to-mesenchymal transition (EMT)-like processes when compared to Rab31 low-expressing cells.
METHODS
Commercially available profiler PCR arrays were applied to search for differentially expressed genes in Rab31 high- and low-expressing CAMA-1 breast cancer cells. Differential expression of selected candidate genes in response to Rab31 overexpression in CAMA-1 cells was validated by independent qPCR and protein assays.
RESULTS
Gene expression profiling of key genes involved in EMT, or its reciprocal process MET, identified 9 genes being significantly up- or down-regulated in Rab31 overexpressing CAMA-1 cells, with the strongest effects seen for TGFB1, encoding TGF-ß1 (> 25-fold down-regulation in Rab31 overexpressing cells). Subsequent validation analyses by qPCR revealed a strong down-regulation of TGFB1 mRNA levels in response to increased Rab31 expression not only in CAMA-1 cells, but also in another breast cancer cell line, MDA-MB-231. Using ELISA and Western blot analysis, a considerable reduction of both intracellular and secreted TGF-ß1 antigen levels was determined in Rab31 overexpressing cells compared to vector control cells. Furthermore, reduced TGF-ß activity was observed upon Rab31 overexpression in CAMA-1 cells using a sensitive TGF-ß bioassay. Finally, the relationship between Rab31 expression and the TGF-ß axis was analyzed by another profiler PCR array focusing on genes involved in TGF-ß signaling. We found 12 out of 84 mRNAs significantly reduced and 7 mRNAs significantly increased upon Rab31 overexpression.
CONCLUSIONS
Our results demonstrate that Rab31 is a potent modulator of the expression of TGF-ß and other components of the TGF-ß signaling pathway in breast cancer cells.
Identifiants
pubmed: 34906074
doi: 10.1186/s10020-021-00419-8
pii: 10.1186/s10020-021-00419-8
pmc: PMC8670132
doi:
Substances chimiques
RAB31 protein, human
0
TGFB1 protein, human
0
Transforming Growth Factor beta1
0
rab GTP-Binding Proteins
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
158Informations de copyright
© 2021. The Author(s).
Références
Small GTPases. 2018 Mar 4;9(1-2):22-48
pubmed: 28632484
Gene. 2013 Oct 25;529(2):199-207
pubmed: 23933273
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16496-501
pubmed: 25369932
PLoS One. 2012;7(7):e39432
pubmed: 22792175
Dev Cell. 2008 Jun;14(6):818-29
pubmed: 18539112
Mol Biol Cell. 2016 Dec 15;27(25):4033-4042
pubmed: 27798239
Carcinogenesis. 2013 Oct;34(10):2401-8
pubmed: 23722651
Curr Opin Genet Dev. 2002 Feb;12(1):22-9
pubmed: 11790550
Semin Cell Dev Biol. 2011 Feb;22(1):57-68
pubmed: 21147240
Nat Cell Biol. 2002 Jul;4(7):487-94
pubmed: 12105419
Dev Dyn. 2006 Jun;235(6):1589-98
pubmed: 16598712
Transl Oncol. 2020 Jun;13(6):100773
pubmed: 32334405
J Cell Biol. 2013 Dec 23;203(6):1063-79
pubmed: 24344185
Nat Rev Cancer. 2010 Jun;10(6):415-24
pubmed: 20495575
J Pathol. 2011 Jan;223(2):205-18
pubmed: 20957627
Oncotarget. 2015 May 10;6(13):11125-38
pubmed: 25823663
Small GTPases. 2015;6(3):135-44
pubmed: 26317377
Eur J Biochem. 2002 Jan;269(1):259-71
pubmed: 11784320
Cancers (Basel). 2020 Jan 21;12(2):
pubmed: 31973201
Dev Dyn. 2018 Mar;247(3):451-461
pubmed: 28390160
Curr Biol. 2009 Dec 29;19(24):R1121-3
pubmed: 20064423
J Cell Sci. 2019 Jun 5;132(11):
pubmed: 31076513
Cell Tissue Res. 2012 Jan;347(1):73-84
pubmed: 21845401
Front Oncol. 2018 Nov 26;8:554
pubmed: 30534536
Am J Cancer Res. 2017 Sep 01;7(9):1959-1970
pubmed: 28979817
PLoS One. 2013 Dec 27;8(12):e84753
pubmed: 24386412
Trends Biotechnol. 2010 Mar;28(3):125-33
pubmed: 20056286
J Biomed Sci. 2016 Oct 6;23(1):70
pubmed: 27716280
J Neurosci Res. 2001 Dec 15;66(6):1149-60
pubmed: 11746448
Cell Death Dis. 2019 Oct 7;10(10):761
pubmed: 31591384
Ann Transl Med. 2020 Jul;8(14):902
pubmed: 32793746
Cancer Res. 2005 Apr 1;65(7):2516-9
pubmed: 15805241
J Biol Chem. 2002 May 17;277(20):18046-52
pubmed: 11877415
Mol Cancer. 2012 Aug 24;11:62
pubmed: 22920728
Breast Cancer Res Treat. 2008 Sep;111(2):229-40
pubmed: 17952591
Semin Cancer Biol. 2017 Feb;42:60-69
pubmed: 27586372
Eur J Cell Biol. 2002 Mar;81(3):138-44
pubmed: 11998865
Oncogene. 2016 Feb 11;35(6):748-60
pubmed: 25961925
Cancer Lett. 2013 Nov 28;341(1):30-40
pubmed: 23474494
FEBS J. 2021 Jan;288(1):36-55
pubmed: 32542850
Nat Protoc. 2016 Apr;11(4):727-46
pubmed: 26985572
Biomaterials. 2007 Sep;28(26):3856-66
pubmed: 17568666
Cell. 2008 Jul 25;134(2):215-30
pubmed: 18662538
PLoS One. 2015 Aug 12;10(8):e0135748
pubmed: 26267863
Mol Neurobiol. 2016 Sep;53(7):4431-7
pubmed: 26245486
Biochem Soc Trans. 2012 Dec 1;40(6):1389-93
pubmed: 23176486
FEBS J. 2009 Jun;276(11):2947-65
pubmed: 19490100
Exp Cell Res. 2009 Aug 1;315(13):2215-30
pubmed: 19345684
J Cell Biol. 2014 Jul 21;206(2):307-28
pubmed: 25049275
J Bone Miner Metab. 2019 Jul;37(4):594-606
pubmed: 30470957
BMC Cell Biol. 2006 Mar 20;7:15
pubmed: 16549026
J Biol Chem. 2020 Feb 28;295(9):2687-2697
pubmed: 31988245
BMC Biol. 2012 Aug 08;10:71
pubmed: 22873208
Nat Rev Mol Cell Biol. 2009 Aug;10(8):513-25
pubmed: 19603039
Nat Commun. 2017 Nov 23;8(1):1741
pubmed: 29170498
Biochem Biophys Res Commun. 2007 Sep 28;361(3):751-7
pubmed: 17678623
Biochim Biophys Acta. 2009 Apr;1795(2):110-6
pubmed: 19425190
Cell Cycle. 2009 Oct 15;8(20):3319-27
pubmed: 19806012
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352
pubmed: 32300252
J Cell Biochem. 2016 Jun;117(6):1279-87
pubmed: 26774024
J Cell Sci. 2015 Sep 1;128(17):3171-6
pubmed: 26272922
J Cell Mol Med. 2015 Jan;19(1):1-10
pubmed: 25472813
Trends Cell Biol. 2010 Jun;20(6):329-36
pubmed: 20227882
Cell Physiol Biochem. 2017;43(1):82-93
pubmed: 28848180
Trends Cell Biol. 2017 Aug;27(8):595-607
pubmed: 28412099